Ambitious Danish biotech fund shuts down before first investment

Ambitions were high when Sund Capital, headed by the former Zealand Pharma CEO David Solomon, announced plans to raise up to DKK 2 billion (EUR 268 million) for investments in up-and-coming biotechs. But now the fund is closing down.

Former Zeland Pharma CEO David Solomon was co-founder of the venture fund Sund Capital

With a total loss of DKK 2.9 million after 18 months, the end has come for Sund Capital which was founded in summer 2016 with the aim of investing up to DKK 2.2 billion in Nordic biotechs.

The revellation comes from the fund's first financial statements covering the period of 5 August 2016 to 31 December 2017.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

PFA says three big changes will bring better returns

To get returns on the same level as other pension firms, PFA has made three big changes to its portfolio, including taking on more risk, says the firm, which doesn't fear a backlash from this year's predicted unsteady market.

Further reading

Latest news


Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch